文献速递间质性肺疾病

抗Ro52抗体阳性间质性肺病与疾病进展和死亡风险升高相关

Association of Anti-Ro52 Seropositive Interstitial Lung Disease With a Higher Risk of Disease Progression and Mortality.
PubMed 文献 · Chest · 2025-06-06

该回顾性队列研究纳入2015至2024年间某三级医院ILD登记中1026例检测抗Ro52抗体的ILD患者,其中154例(15%)阳性。

要点

  • 抗Ro52抗体在ILD患者中阳性率15%,阳性者更年轻且更常合并结缔组织病。
  • 抗Ro52阳性与ILD进展或死亡风险升高独立相关(HR 2.10)。
  • 抗Ro52阳性与肺移植或死亡风险升高相关(HR 1.61)。

核心结论

  • 抗Ro52抗体阳性ILD与显著更差的無进展生存和无移植生存相关,可能有助于疾病预后判断和监测。

研究设计与样本

  • 回顾性队列研究,使用2015至2024年某学术三级医院ILD门诊的ILD登记数据。
  • 共纳入1026例确诊ILD且检测抗Ro52抗体状态的患者,分为阳性组和阴性组。
  • 主要结局为ILD进展或全因死亡;ILD进展定义为因ILD住院、FVC较基线绝对下降≥10%预计值或肺移植。

主要发现

  • 1026例患者中154例(15%)抗Ro52抗体阳性;中位年龄70岁,52%为男性。
  • ILD亚型分布:具有自身免疫特征的间质性肺炎489例(48%),结缔组织病相关ILD 132例(13%),特发性肺纤维化103例(10%),过敏性肺炎61例(6%),其他特发性ILD 241例(24%)。
  • 抗Ro52阳性组较阴性组更年轻(中位年龄67岁 vs 70岁),更常合并结缔组织病(28% vs 10%),更常合并肌炎特异性抗体阳性(29% vs 16%)。

临床怎么用

  • 对ILD患者检测抗Ro52抗体可能有助于识别进展和死亡风险较高的亚组。
  • 抗Ro52阳性ILD患者可能需要更密切的疾病进展监测和预后评估。

局限性

  • 回顾性队列研究设计,可能存在选择偏倚和未测量混杂。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identifying biomarkers is vital for interstitial lung disease (ILD) management and prognostication. Although anti-Ro52 antibodies frequently are detected in autoimmune diseases, their significance in ILD remains unclear. RESEARCH QUESTION: What is the prognostic significance of anti-Ro52 antibody positivity in patients with ILD? STUDY DESIGN AND METHODS: This retrospective cohort study used an ILD registry of patients seen at an academic tertiary hospital's ILD clinic between 2015 and 2024. All patients with a diagnosis of ILD and tested for anti-Ro52 antibody status were divided into anti-Ro52 positive and negative groups. The primary outcome was ILD progression or all-cause death. ILD progression was defined as any of the following: hospitalization because of ILD, absolute decline in FVC of ≥ 10% predicted from baseline, or lung transplantation. The Kaplan-Meier method and Cox proportional hazards regression model were used for survival analysis. RESULTS: Of 1,026 patients tested for the anti-Ro52 antibody (median age, 70 years; 52% male), 154 patients (15%) showed positive anti-Ro52 results. Underlying ILD subtypes were as follows: interstitial pneumonia with autoimmune features (n = 489 [48%]), connective tissue disease-associated ILD (n = 132 [13%]), idiopathic pulmonary fibrosis (n = 103 [10%]), hypersensitivity pneumonitis (n = 61 [6%]), and other idiopathic ILD (n = 241 [24%]). The anti-Ro52-positive group was younger (median age, 67 years vs 70 years), was more likely to have connective tissue disease (28% vs 10%), and more frequently showed copositive results for myositis-specific antibody (29% vs 16%). After a median follow-up of 25.6 months, patients with positive anti-Ro52 findings showed a higher risk of ILD progression or death (hazard ratio, 2.10; 95% CI, 1.61-2.73; P < .001) and showed a higher risk of lung transplantation or death (hazard ratio, 1.61; 95% CI, 1.11-2.35; P = .014) on multivariable analysis. INTERPRETATION: Our results indicate that Anti-Ro52-seropositive ILD is associated with significantly worse progression-free and transplant-free survival and may inform disease prognostication and monitoring.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Imai R, Bermea RS, Zhao SH, et al. Association of Anti-Ro52 Seropositive Interstitial Lung Disease With a Higher Risk of Disease Progression and Mortality. Chest. 2025. PMID: 40484372. doi:10.1016/j.chest.2025.05.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。